Holen Sie sich die Stockscreener-App
26.94
4.87%
1.25
Handel nachbörslich:
26.64
-0.30
-1.11%
Schlusskurs vom Vortag:
$25.69
Offen:
$25.55
24-Stunden-Volumen:
411.68K
Relative Volume:
1.77
Marktkapitalisierung:
$772.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.91M
KGV:
-10.95
EPS:
-2.46
Netto-Cashflow:
-
1W Leistung:
+15.87%
1M Leistung:
+13.29%
6M Leistung:
+77.94%
1J Leistung:
+0.00%
1-Tages-Spanne:
$24.70
$27.02
1-Wochen-Bereich:
$22.51
$27.02
52-Wochen-Spanne:
$13.36
$27.55
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
26.94 | 736.66M | 0 | -56.91M | 0 | -2.46 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
LB Pharmaceuticals Presents New Data on LB-102's Potential to Improve Cognitive Performance in Schizophrenia - National Today
LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting By Investing.com - Investing.com Australia
LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting - Investing.com
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) - ChartMill
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Releases Quarterly Earnings Results, Meets Estimates - marketbeat.com
Stifel raises LB Pharmaceuticals stock price target to $40 By Investing.com - Investing.com India
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX: LB-102 shows strong efficacy and safety in late-stage trials, targeting major neuropsychiatric markets - TradingView
LB Pharmaceuticals (NASDAQ: LBRX) advances LB-102 in schizophrenia and bipolar depression - Stock Titan
LB Pharmaceuticals Inc Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot - Barchart.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
LB Pharmaceuticals commences Phase III schizophrenia trial - Yahoo
LB Pharmaceuticals starts phase 3 trial for schizophrenia drug By Investing.com - Investing.com India
LB Pharmaceuticals starts phase 3 trial for schizophrenia drug - Investing.com
LB Pharmaceuticals initiates pivotal phase 3 trial (Nova-2) for LB-102 in patients with schizophrenia - marketscreener.com
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia - The Manila Times
LB Pharmaceuticals Inc Initiates Pivotal Phase 3 Trial for LB -102 in Patients with Schizophrenia - MarketScreener
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P Global BMI Index - MarketScreener
LB Pharmaceuticals Inc(NasdaqGM:LBRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029 - MarketBeat
LB Pharmaceuticals Inc: Fundamental Analysis and Financial Ratings | LBRX | US50180M1080 - marketscreener.com
LBRX: LB-102 advances toward pivotal data in major CNS indications, fully funded through 2029 - TradingView
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.6%Should You Sell? - MarketBeat
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting - Investing.com India
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting By Investing.com - Investing.com South Africa
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) director to retire and serve as consultant - Stock Titan
Boxer Capital Management LLC Acquires Shares of 70,000 LB Pharmaceuticals Inc $LBRX - MarketBeat
Commodore Capital LP Invests $23.69 Million in LB Pharmaceuticals Inc $LBRX - MarketBeat
200,000 Shares in LB Pharmaceuticals Inc $LBRX Bought by Baker BROS. Advisors LP - MarketBeat
300,000 Shares in LB Pharmaceuticals Inc $LBRX Acquired by Nan Fung Group Holdings Ltd - MarketBeat
100,000 Shares in LB Pharmaceuticals Inc $LBRX Purchased by Integral Health Asset Management LLC - MarketBeat
LB Pharmaceuticals appoints Robert Lenz to board of directors By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
LB Pharmaceuticals (LBRX) director receives 20,000 stock options vesting 2027–2029 - Stock Titan
LB Pharmaceuticals (LBRX) director Robert Lenz files initial Form 3 - Stock Titan
LB Pharmaceuticals adds neuroscience leader to board, governance - TipRanks
LB Pharmaceuticals (Nasdaq: LBRX) names new director and COO - Stock Titan
LB Pharmaceuticals Inc Approves the Promotion of Gad Soffer, the Chief Business Officer, to the Position of Chief Operating and Business Officer, Effective March 4, 2026 - marketscreener.com
Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
3,433,470 Common Stock of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
LB Pharmaceuticals appoints Robert Lenz to board of directors - Investing.com
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors - Bitget
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lb Pharmaceuticals Inc-Aktie (LBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):